RESHMI GORDHAN: Open Payments
NPI 1063914737 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,885 in 59 payments from 9 companies in 2025. Trend: 2023 $1,288 · 2024 $3,286 · 2025 $2,885
Food & beverage: $2,786Education: $100
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 15 | $731 |
| Teva Pharmaceuticals USA, Inc. | 10 | $577 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $496 |
| Vanda Pharmaceuticals Inc. | 9 | $373 |
| Otsuka America Pharmaceutical, Inc. | 5 | $328 |
| Axsome Therapeutics, Inc. | 2 | $149 |
| Lundbeck LLC | 4 | $107 |
| ABBVIE INC. | 4 | $101 |
| Alkermes, Inc. | 1 | $23 |
Products named: COBENFY, CAPLYTA, FANAPT, UZEDY, ABILIFY MAINTENA, REXULTI, Auvelity, AUSTEDO XR.
Industry payments across NY — which companies pay providers there.
